Pfizer’s CIFFREO Phase 3 study in DMD fails to meet primary endpoint
Pfizer Inc. (NYSE: PFE), a global leader in pharmaceuticals, faced a setback as their CIFFREO Phase 3 study did not meet its primary endpoint. The study aimed to evaluate the effectiveness of the investigational mini-dystrophin gene therapy, fordadistrogene movaparvovec, in improving motor function among ambulatory boys with Duchenne muscular dystrophy (DMD) aged 4 to 7 […]